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AbstrACt
Objectives While very early mobilisation (VEM) 
intervention for stroke patients was shown not to be 
effective at 3 months, 12 month clinical and economical 
outcomes remain unknown. The aim was to assess cost-
effectiveness of a VEM intervention within a phase III 
randomised controlled trial (RCT).
Design An economic evaluation alongside a RCT, and 
detailed resource use and cost analysis over 12 months 
post-acute stroke.
setting Multi-country RCT involved 58 stroke centres.
Participants 2104 patients with acute stroke who were 
admitted to a stroke unit.
Intervention A very early rehabilitation intervention within 
24 hours of stroke onset
Methods Cost-utility analyses were undertaken according 
to pre-specified protocol measuring VEM against usual 
care (UC) based on 12 month outcomes. The analysis 
was conducted using both health sector and societal 
perspectives. Unit costs were sourced from participating 
countries. Details on resource use (both health and 
non-health) were sourced from cost case report form. 
Dichotomised modified Rankin Scale (mRS) scores (0 to 
2 vs 3 to 6) and quality adjusted-life years (QALYs) were 
used to compare the treatment effect of VEM and UC. The 
base case analysis was performed on an intention-to-treat 
basis and 95% CI for cost and QALYs were estimated by 
bootstrapping. Sensitivity analysis were conducted to 
examine the robustness of base case results.
results VEM and UC groups were comparable in the 
quantity of resource use and cost of each component. 
There were no differences in the probability of achieving 
a favourable mRS outcome (0.030, 95% CI −0.022 to 
0.082), QALYs (0.013, 95% CI −0.041 to 0.016) and 
cost (AUD1082, 95% CI -$2520 to $4685 from a health 
sector perspective or AUD102, 95% CI -$6907 to $7111, 
from a societal perspective including productivity 
cost). Sensitivity analysis achieved results with mostly 
overlapped CIs.
Conclusions VEM and UC were associated with 
comparable costs, mRS outcome and QALY gains at 12 
months. Compared with to UC, VEM is unlikely to be cost-
effective. The long-term data collection during the trial also 
informed resource use and cost of care post-acute stroke 
across five participating countries.
trial registration number ACTRN12606000185561; 
Results.
IntrODuCtIOn
Stroke is one of the biggest killers and a 
leading cause of disability worldwide.1 2Sixty 
five per cent of stroke survivors live with some 
degree of disability that impedes their ability 
to carry out daily living activities unassisted.3 
Therefore, ways of improving the outcomes 
of patients after stroke is an important focus 
of research.4 5 Early mobilisation after stroke 
is believed to contribute to better patient 
outcomes and clinical trials have been 
conducted globally.6–9 
The short-term efficacy and safety of a very 
early rehabilitation trial after stroke (AVERT) 
has been evaluated in a phase III randomised 
controlled trial (RCT) with 2104 patients 
enrolled from Australia, New Zealand, UK, 
Singapore and Malaysia.10 The evidence 
from this trial indicated that at 3 months 
after stroke, very early mobilisation (VEM) 
of patients was associated with a reduction 
in the probability of a favourable outcome as 
defined by a modified Rankin Scale (mRS) 
score of 0 to 2 compared with that in the 
strengths and limitations of this study
 ► This is the first economic evaluation assessing the 
cost-effectiveness of a very early rehabilitation in-
tervention within the largest phase III randomised 
controlled trial in patients with stroke.
 ► The study assessed the long-term cost and cost-ef-
fectiveness of this very early rehabilitation interven-
tion at 12 month.
 ► The difficulty posed by the multi-country design of 
the trial and the percentage of missing data may un-
dermine the confidence in the results. copyright.
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usual care (UC) group.10 In the research field of stroke, 
primary endpoint is usually assessed at month 3 after 
stroke,11–14 which means there is a paucity of data in terms 
of long-term resource use and cost of care for patients 
with stroke. Given AVERT provided a longer-term (ie, 12 
months) comprehensive measurement of costs relating 
to stroke care (ie, direct medical, direct non-medical 
and indirect costs), and the broader representativeness 
of patients across countries and regions (>2000 patients 
were recruited from both developing and developed 
world), together with the implications of stroke economic 
burden sustained beyond the acute phase (ie, 3 months), 
holistically examining the cost of stroke care that falls 
within health and non-health sectors could potentially 
advance understanding of pattern of resource use post 
stroke and identify any gaps to improve care for stroke 
and chances to curb the increasing economic burden 
of disease. This examination also benefits healthcare 
funders (ie, governments, insurance companies) and the 
public with addition of substantial knowledge of long-
term rehabilitation cost for stroke.
This economic evaluation, which was part of the regis-
tered trial protocol (Australian New Zealand Clinical 
Trials Registry, ACTRN12606000185561) and planned 
prior to knowledge of outcomes, was conducted along-
side the phase III RCT,10 The aim of this paper is to 
assess the cost-effectiveness of very early mobilisation 
within 24 hours after stroke in terms of improving patient 
outcomes at 12 months, in comparison to usual care, with 
a particular focus on examining the resource use and cost 
of care after stroke.
MethODs
The economic analysis was undertaken following the 
previously published plan.15 It also conforms to the 
Consolidated Health Economic Evaluation Reporting 
Standards checklist.16 Ethics approval was granted by rele-
vant institutions.
Intervention and comparator
The trial design has been reported in detail elsewhere.10 
In brief, patients with confirmed stroke who were 
admitted to a stroke unit within 24 hours of stroke onset 
were randomised to receive usual stroke-unit care alone 
or VEM in addition to UC in a multinational phase III 
trial.
Outcomes
The mRS at 12 months, a secondary outcome of the trial, 
and quality-adjusted life years (QALYs) derived from the 
assessment of quality of life-4 dimension (AQoL-4D)17 
were used as the effectiveness measures in the economic 
evaluation. The AQoL-4D instrument is a multi-attribute 
utility scale used to assess the health-related quality of life 
(HRQoL)18; it was administered at 3 and 12 months.
Outcome of mRS was dichotomised into ‘favour-
able’ (mRS 0 to 2) and ‘poor’ (mRS 3 to 6) based on 
patients outcomes at 12 month follow-up.10 The differ-
ence in the probability of patients achieving a favourable 
mRS outcome (mRS 0 to 2) was used to estimate the 
incremental benefits between treatment groups for the 
primary efficacy outcome.
Due to the inherent difficulties of administering the 
AQoL instrument to acute stroke patients (ie, most of 
patients were not able to respond to these questions at 
baseline), the mRS score at baseline10 was used as a surro-
gate measure of patient utility during the acute phase. 
The detailed methods of this work are reported else-
where19 and a brief description is supplied in the online 
supplementary document 1.
Costs
A societal perspective with a key focus on the health sector 
was adopted.
Intervention delivery
Intervention delivery costs consisted of the time costs of 
physiotherapists (PT) and nurses delivering VEM (or UC) 
to patients. The mean of the total physiotherapist time 
(recorded by a log documented by each participating PT 
across whole hospital stay) per patient was calculated. 
Given insufficient data, physiotherapist’s mean time per 
session was used as a proxy for nurse time spent on deliv-
ering either VEM or UC.
Resource use
All resource use during the study period was electroni-
cally collated using a validated cost case report form 
(Cost CRF) administered and recorded by trained staff 
at 3 and 12 months using face-to-face assessments with 
patients and carers, and medical records. Cost CRF used 
in Australia is supplied as an example (online supple-
mentary document 2). Cost CRF from other participating 
countries could be requested from corresponding author.
Healthcare resource use
The quantity of resources used for the following health-
care resource items was recorded: number of ambulance 
transfers (emergency and non-emergency), acute hospi-
talisation (including length of stay (LoS)), rehospitalisa-
tion (number of occasions and LoS for each occasion), 
rehabilitation hospital admission (number of occasions 
and LoS for each occasion), outpatient rehabilitation 
programme (number of occasions and number of days for 
each occasion), rehabilitation provided at home/nursing 
facility (number of occasions and number of sessions 
for each occasion), private physiotherapy (number of 
sessions), respite care (number of sessions) and indi-
vidual outpatient (including physiotherapy, occupational 
therapy and speech and language therapy) visits (service 
type and number of sessions) for patients from UK, Singa-
pore and Malaysia only.
Non-healthcare resource use
The quantity of resources used was recorded for the 
following non-healthcare resource items: accommodation 
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move due to stroke (location moved to and date of move), 
community service (type of service use and number of 
service used both for prior to and post stroke), home 
modification (type of modification, supplier and cost), 
special equipment and aids (type of equipment/aids and 
quantity consumed), informal care (purpose of the care 
and hours used), live-in maids (number of maids prior 
to and post stroke) (for Singapore and Malaysia only), 
changes to employment (employment status and weekly 
hours of working both prior to and post stroke).
Resource use reported at 3 (ie, resources used between 
0 and 3 months) and 12 (ie, resources used between 4 
and 12 months) months was used to calculate the total 
annual resource use for each participant. Generally, 
where patients were still using a particular resource at 
the time of 12 month data collection, the last day of 12 
months’ follow-up (calculated from the day of index 
stroke) was used to estimate the duration of that resource 
utilisation. In the event of a patient dying, resource use 
data for the period prior to death was ascertained from 
their carer and medical records, wherever possible.
Unit costing
Costs were computed by applying country-specific unit 
costs to each resource item utilised. Therefore, five sets 
of unit costs (one for each of the participating countries) 
were compiled from the most up-to-date and reliable 
source (online supplementary document 3). Unit costs 
from a country with a similar economic status and health-
care system were used where local country-specific unit 
costs were unavailable.
All costs are expressed in Australian dollars (AUD) for 
the 2015 reference year value and can be converted to 
US dollar (USD) using the purchasing power parity rate 
1 USD=1.463 AUD20 (December 2015). The currency of 
other countries was converted to AUD using the corre-
sponding exchange rate. The country-specific consumer 
price index from the health sector was employed to adjust 
costs not valued in the year of 2015.
The details of unit cost for acute stroke hospitalisation, 
rehospitalisation, rehabilitation (inpatient and outpa-
tient), non-health sector costs (home modifications, 
community services, aids, etc) and productivity cost are 
provided in online supplementary document 3.
statistical analysis
All the costs that were attributable to stroke including 
healthcare costs, non-healthcare costs and productivity 
costs were accounted for in the economic analysis. Since 
a 12 month economic evaluation was undertaken, no 
discounting was applied to either costs or benefits.
Quantity of resource use and costs were summarised 
using medians and IQRs due the skewness of the raw data. 
Means and SDs were also reported. Base case analysis of the 
economic evaluation was performed based on the inten-
tion-to-treat (ITT) population21 with an assumption for the 
main analysis that data were missing at random (MAR). 
The difference in costs was analysed using generalised 
linear regression model (GLM) with gamma family and a 
log link, with treatment groups as an independent variable, 
including baseline National Institutes of Health Stroke Scale 
(NIHSS), baseline mRS15 and age as treatment covariates.
For the primary outcome, the mRS score at 12 months 
was compared following the method detailed in the statis-
tical analysis plan.22 While for the secondary effectiveness 
outcome (ie, the QALY gains at 12 months), a linear 
regression model with treatment group as the factor vari-
able and 12 months AQoL-4D utility value as the depen-
dent variable, adjusted for age, baseline mRS was utilised 
to estimate the difference in QALY gains over 12 months. 
Non-parametric bootstrap simulations with 2000 replica-
tions were used to calculate 95% CIs around mean differ-
ence in costs and effects for cost-effectiveness analysis. To 
examine the cost-effectiveness of VEM measured against 
UC, incremental cost-effectiveness ratios (ICERs) were 
calculated where applicable. For the ICER from a soci-
etal perspective, all the costs from health and non-health 
sector were summed together, including the productivity 
cost; for ICER of a health sector perspective, all the costs 
borne by healthcare system were counted (ie, excluding 
non-healthcare costs and productivity cost). The differ-
ences between groups in terms of costs and benefits 
(ie, QALYs) were compared regardless of the statistical 
significance of the difference.23 Cost-effectiveness accept-
ability curves were plotted to show the probability of VEM 
being the optimal choice. The ICERs were compared 
with a common benchmark in Australia of ≤AUD50,000 
per QALY.24 All the analyses were performed using the 
STATA V.14.0 statistical package.
sensitivity analyses
To investigate the impact of using country-specific costs, a 
country dummy variable was added to the GLM analysis to 
adjust for country effect.25 Subgroup analysis on the basis 
of individual countries were also conducted to explore 
the difference in costs and benefits across countries.
Multiple imputation was performed to test the sensitivity 
of results to the missing data assumption. The missing 
patterns were explored with the use of logit regression to 
investigate if any of the other variables predicted whether 
a given variable was missing26 (online supplementary docu-
ment 4).
Secondary analyses were undertaken to assess the 
robustness of the base case results. Subgroup analyses 
were performed at the country-specific level to test for 
differences in efficacy and costs.
Patient and public involvement
No patient and public were involved.
results
Between July 2006 and October 2014, 2104 patients 
(VEM 1054, UC 1050) were recruited across 58 sites 
from Australia (n=1054, 24 sites), New Zealand (n=189, 
one site), UK (n=610, 29 sites), Singapore (n=128, one 
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site) and Malaysia (n=123, one site). At recruitment, over 
80% of patients had no prior history of stroke; NIHSS was 
greater than 7 points (indicating a moderate-to-severe 
stroke) for around 45% of patients; 26% aged over 80 
years and 24% had received recombinant tissue plasmin-
ogen activator prior to randomisation.10 Baseline charac-
teristics were similar between the two treatment groups.10
Outcomes
There was no difference between VEM and UC groups 
in terms of favourable mRS outcome and quality of life 
(as measured by AQoL-4D) at month 12. Specifically, a 
comparable percentage of patients from both treatment 
groups achieved a favourable outcome at 12 months 
after stroke (between-group difference in probability: 
0.030, 95% CI −0.021 to 0.082, adjusted for baseline age 
and NIHSS). Likewise, for the outcome of AQoL-4D at 
12 months, no between-group difference was observed 
(−0.013, 95% CI −0.043 to 0.017). The detailed mRS 
outcomes are presented in online supplementary docu-
ment 5: table I.
resource use and costs
The proportion of patients reporting use of a specific 
resource varied from item to item (table 1). In relation to 
the healthcare resource items, nearly half of the patients 
experienced rehabilitation hospital admission and more 
than a quarter of the patients had a stroke-related rehospi-
talisation, rehabilitation service use (outpatient/provided 
at home or nursing facility) and ambulant transfers 
whereas only a small proportion of the patients (less than 
10%) recorded the use of private physiotherapy and/or 
respite care. Regarding non-health-related resource use, 
the majority of patients (>50%) used some form of special 
aids or equipment during the 12 months after their index 
stroke, while nearly 40% of patients received informal 
care and around 27% reported the use of community 
services and home modifications. Only 16% (VEM) and 
17% (UC) of patients respectively, experienced accom-
modation changes due to the index stroke. For maid’s 
service use in the home in Singapore and Malaysia, a 
small proportion (less than 10%) of the patients hired a 
maid both before and after the index stroke.
With respect to productivity, nearly one in four patients 
were employed prior to their stroke; this proportion fell 
to only one in eight patients at 12 months follow-up. 
Generally, resource use was comparable between VEM 
and UC groups (p>0.05) across all items (table 1).
The median total medical cost was marginally higher in the 
UC group ($20 411, IQR $7238 to $63 835) than in the VEM 
group ($19 271, IQR $6294 to $52 637), primarily due to the 
higher rehabilitation admission cost in UC. In both groups, 
the major cost component was acute hospitalisation which 
accounted for around 30% of medical costs. The median 
non-medical cost was also marginally higher in the UC group 
($438, IQR $0 to $4561) than in the VEM group ($358, IQR 
$0 to $3334). The median productivity cost was zero for 
both treatment groups given that less than one quarter of 
patients were in paid employment before the index stroke. 
Overall, the median total cost (including productivity cost 
and non-medical costs) were nominally higher in the UC 
group ($27 042, IQR $7257 to $63 824) compared with the 
VEM group ($25 675, IQR $6766 to $63 617). The detailed 
costs of each resource item and summary costs are presented 
in table 2. The costs for VEM and UC interventions are 
summarised in online supplementary document 5: table II.
Generally, the cost from VEM and UC groups were 
comparable: the differences between VEM and UC 
groups was $1082 (95% CI  -$2399 to $4563) for the total 
medical cost (online supplementary document 6: table I) 
and $3 (95% CI -$5 to  $12) for the productivity cost per 
person at 12 months; the between-group difference in the 
total non-healthcare cost was -$1300 (95% CI -$3361 to 
$760) over the same period of time.
Cost-effectiveness analysis
The between-group difference in both efficacy and cost 
outcomes generated from the GLM model are presented 
in online supplementary document 6: table I.
In the base case health sector perspective analysis, the 
VEM yielded comparable total medical costs ($1082, 
95% CI -$2520 to $4685, p=0.544) and QALY gains 
(−0.013, 95% CI −0.041 to 0.016) at 12 months. When 
a societal perspective was adopted, the VEM entailed, 
again, similar costs with the UC group ($102, 95% CI 
-$6907 to $7111, p=0.982, including productivity costs) or 
(-$6, 95% CI -$5476 to $5463, p=0.933, excluding produc-
tivity costs) (table 3).
The cost-effectiveness planes and cost-effectiveness 
acceptability curves from the two perspectives are shown 
in online supplementary document 7: figures I to V.
sensitivity analyses
Inclusion of a country dummy variable in the analysis 
produced similar results to the base case (online supple-
mentary document 6: table II).
The analysis from imputed data including all randomised 
participants produced consistent results with regard to 
the incremental cost and effectiveness between treatment 
groups. For example, from a health sector perspective, 
VEM was associated with similar costs ($940, 95% CI $−4622 
to $4682) and QALY gains (−0.019, 95% CI−0.044 to 0.005) 
over 12 months. (online supplementary document 6: table 
III and online supplementary document 7: figures VI-VIII)
The country-specific analysis showed similar results in 
the between-group differences for both costs and QALYs, 
indicating that VEM and UC yielded comparable results 
within each participating countries (table 4).
When a societal perspective was assumed, again, the 
point estimate of difference in costs between groups 
across countries varied substantially, with the 95% CIs 
mostly overlapping (table 4).
DIsCussIOn
The 12 months within-trial cost-effectiveness analysis 
showed that VEM was unlikely to be cost-effective than 
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UC in patients with stroke. Between-group differences 
in costs and benefits (probability of achieving a favour-
able outcome of mRS and differences in QALYs) over the 
1 year study period were comparable from a health sector 
perspective. The findings from this economic evaluation 
is also underpinning an adapted version of trial under way 
to investigate the effectiveness of optimal rehabilitation in 
patients with mild-to-moderate stroke (ie, AVERT-DOSE, 
National Health and Medical Research Council Australia, 
project grant #1139712).
Our earlier economic evaluation of the phase II AVERT 
trial which consisted of only 71 patients (38 VEM and 
33 UC) from two Australian centres reported that VEM 
was likely to be a cost-effective intervention with both 
less cost and more benefit when compared with UC.27 
Since it was a national pilot study with a limited sample, 
the direct comparison between the results from this and 
our current economic evaluation is problematic. In addi-
tion, inconsistent with the pilot study, no service shifting 
was observed in the current study. Across all resource 
use components, the proportion of patients consuming 
specific types of resources were comparable between the 
two groups in this study. On the contrary, in the phase II 
AVERT trial, patients from VEM group were more likely to 
be discharged earlier from hospital than their UC coun-
terparts; those discharged early tended to use more care 
provided in the outpatient setting, which incurred lower 
costs and informal care was not costed. In the current 
study, the LoS for acute hospitalisation and rehabilitation 
were similar between treatment groups (median: VEM 16 
vs UC 17 days). These differences between the two studies 
highlight the importance of large, adequately powered 
studies to inform healthcare policy.
In this study, resources used were valued on the basis 
of country-specific unit costs sourced for each partici-
pating country. To counteract any concern arising from 
the adoption of this approach, extensive sensitivity anal-
yses were performed to test the robustness of the results. 
The conduct of incorporation of a country dummy vari-
able into the model or country-specific analysis did not 
alter the outcomes substantially, with the resultant 95% 
CIs overlapping to a great extent. Ramsey et al 2015 
suggest that a country-specific costing approach is likely 
to yield few qualitative differences in summary measures 
of cost-effectiveness among countries with similar levels 
of economic development.25 Therefore, it was believed 
that any differences in economic status of the partici-
pating countries (as reflected by the unit costs applied in 
our study) are unlikely to bear a major influence on the 
results of the cost-effective analysis.
This multinational trial also revealed that in managing 
patients post-stroke, practice of stroke care varied from 
country to country. Although 100% of patients with stroke 
were hospitalised for the initial acute care, the LoS differs 
significantly greatly, ranging from 4 days (Malaysia) to 25 
days (New Zealand), which might be attributable to the 
different severity of stroke and/or differences in clinical 
practice care processes. Moreover, in Malaysia, patients 
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tended to receive rehabilitation services in an outpatient 
(ie, up to 52% of patients received the outpatient reha-
bilitation programme services) rather than inpatient (ie, 
only up to 2% patients were admitted to rehabilitation 
hospital) setting; and patients were less likely to use ambu-
lant transfer and apply home modifications, as compared 
with participants from other countries. This might be a 
signal for future study around stroke care in Malaysia, 
research potentially could be helpful to improve the 
service delivery for outpatient rehabilitation programme. 
Patients from western countries consumed more commu-
nity services and rehabilitation services that provided 
at home/nursing home than their Asian counterparts, 
which reflects the difference in social welfare and health-
care systems.
Economic evaluations have been conducted for other 
types of stroke rehabilitation interventions including 
early-supported discharge service, community- or home-
based rehabilitation.28–36 Generally, these interventions 
trended towards being cost-saving measured against usual 
practice. In regards to HRQoL outcomes measured by 
a series of quality of life instruments (including SF-36, 
WHOQoL-Bref, Nottingham Health Profile, Sickness 
Impact Profile and EQ-5D), most studies did not detect 
an overall significant effect.28–32 34 35 37 Only one study 
reported a significant difference improvement in the 
overall HRQoL score.36 The conclusions drawn from these 
economic evaluations of stroke rehabilitation interven-
tions were fairly consistent; the interventions were likely 
to cost less,33 34 37–42 although the difference in costs was 
statistically significant in only one study.41 None of these 
studies evaluated the costs and benefits, particularly bene-
fits measured in terms of QALYs, in an aggregated manner, 
and all were limited by small sample sizes. Another study 
using a Markov model explored the increased intensity 
of physiotherapy for stroke patients from a health system 
perspective, concluding that increased physiotherapy 
could be cost-effective by improving health outcomes and 
reducing costs due to the resultant shorter stay in rehabil-
itation facilities.43
Given that it is not practical to obtain a baseline utility 
value from patients with stroke, in this study, the base-
line AQoL value was mapped from mRS score at base-
line.15 While the mapping exercise was carried out using 
the baseline mRS score and AQoL values at 3 and 12 
months, the significant variation in the mapped baseline 
utility values for patients falling within the same category 
of mRS hampered its application to the current economic 
evaluation. Instead, only the 12 month utility values were 
compared with to approximate the difference in QALY 
Table 3 Baseline cost-utility analysis ITT
QALYs Per capita mean cost (AUD)
Healthcare perspective
  Total medical costs −0.013
(−0.041, 0.016)
$1082
(-$2520, $4685)
Societal perspective
  Total medical and non-medical costs (excl. productivity cost) −0.013
(−0.041, 0.016)
-$6
(-$5476, $5463)
  Total medical and non-medical costs (incl. productivity cost) −0.013
(−0.041, 0.016)
$102
(-$6907, $7111)
AUD, Australian dollar; excl., excluding; incl., including; ITT, intention-to-treat; QALYs, quality-adjusted life years.
Table 4 Results of country-specific analysis of costs and benefits
AU
(n=1054)
NZ
(n=189)
UK
(n=610)
SG
(n=128)
MA
(n=123)
Total medical costs $948 (−$4352, 
$6248)
−$2836 (−$8403, 
$2730)
$2937 (−$3635, 
$9509)
−$81 (−$2789, 
$2627)
$137 (−$324, 
$599)
Total non- medical 
costs
−$1318 (−$3038, 
$403)
−$3959 (−$7769, 
-$150)
−$1387 (−$7331, 
$4557)
−$3164 (−$6834, 
$505)
$200 (−$232, 
$631)
Total cost (incl. 
productivity) 
−$1735 (−$8482, 
5013)
−$8981 (−$18 380, 
$418)
$1870 (−$13 955, 
$17 694)
−$2636 (−$9233, 
$3961)
$479 (−$487, 
$1446)
Total cost (excl. 
productivity) 
-$1185 (-$7184, 
$4815)
−$7610 (−$15 302, 
$82)
$2552 (−$11377, 
$16 481)
−$1534 (−$6464, 
$3395)
$416 (−$364, 
$1196)
QALY gains −0.036 (−0.076, 
0.003)
0.086 (−0.003, 
0.176)
−0.010 (−0.064, 
0.044)
0.008 (−0.106, 
0.123)
0.003 (−0.126, 
0.132)
*The p value was >0.05 for the between-group difference in QALYs and cost.
AU, Australia; excl., excluding; MA, Malaysia; NZ, New Zealand; QALY, quality-adjusted life year.; SG, Singapore; UK, United Kingdom.
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gains over 1 year between the two treatment groups. 
Comprehensive sensitivity analyses were undertaken 
surrounding this assumption. It was observed that there 
was no noticeable difference among approaches exam-
ining the annual QALY gain difference between VEM and 
UC.
While the results from the clinical study showed that 
there were no significant differences in either costs or 
effects between treatment groups, the cost-effectiveness 
analysis was still performed to investigate the possible 
ICER of the VEM intervention. It is possible to have 
greater confidence in the joint outcome of costs and 
QALYs than looking at them individually.44
To the best of our knowledge, this study evaluated the 
cost-effectiveness of the largest international acute stroke 
rehabilitation trial ever conducted. The cost-effective-
ness analysis was performed alongside the randomised 
controlled trial, where the costs and benefits data were 
collected prospectively. Moreover, the Cost CRF was 
completed by trained and blinded assessors via inter-
views with individual patients/carers and accessing 
medical records, which provides for greater accuracy 
than resource use questionnaires or diaries completed by 
participants themselves. Since the trial was designed in a 
pragmatic manner, with close resemblance to real clinical 
practice, it is believed that the assessment of its cost and 
cost-effectiveness under this setting reflects the real-life 
resource use (health and non-health).
This study provides some insights for future economic 
evaluation alongside multi-country, multi-centre clinical 
trials. It is important to note that given the large number 
of centres involved (56 stroke units across five geograph-
ical jurisdictions), it was not practical or reasonable to 
collect centre-specific unit costs which probably leads 
to huge variations even within a single country. Coun-
try-level unit costs were therefore applied to the valua-
tion of resource uses across the trial sites. However, the 
heterogeneity in the resource utilisation and unit cost 
among the included countries undermines confidence in 
the conclusion. A country-specific economic evaluation 
might be more appropriate in this regard but the lacking 
of statistical power poses another concern. The current 
study made a trade-off between them both approaches by 
presenting both the aggregated (ie, base case of pooling 
all countries) and disaggregated (ie, sensitivity analysis of 
individual countries) form of results. The resource util-
isation, costs and benefits were also tabulated across all 
sites and individually to allow close scrutiny from various 
perspectives.28 It is believed that this practice can be 
recommended to other multi-country studies.
A couple of limitations of the study are acknowledged. 
First, the missing data on total costs from a societal 
perspective was around 24%, and related mainly to the 
missing information on community services (10.9%) 
and productivity loss (10.7%). The base case analysis 
was based on the ITT population with an assumption of 
missing pattern being MAR. To account for this, the sensi-
tivity analysis using multiple imputation was undertaken 
and yielded the identical conclusion (ie, comparable 
results in costs and benefits between treatment groups). 
Second, unit costs originating from individual countries 
were assigned to value resource use. The differences in 
healthcare systems and cost structures among the five 
participating countries may potentially confound the 
cost comparisons between groups. However, analysis by 
country produced results consistent with the base case, 
which overcomes any concern that the latter were heavily 
weighted towards Australia, the largest sample country.
COnClusIOns
This economic evaluation alongside a phase III RCT 
evidenced that based on the ITT population, the VEM 
intervention for patients with stroke was unlikely to be 
cost-effective compared with UC. The sensitivity analyses 
based on the multiple imputation and subgroup analyses 
by each country separately yielded fairly consistent results. 
Despite substantial differences observed, in resource use 
and unit costs across the countries, the marginal differ-
ences between VEM and UC were consistent. Overall, 
the VEM intervention was demonstrated to be compa-
rable with UC in terms of both benefits and costs at 
1 year, however given its poorer outcomes at 3 months, 
VEM cannot be recommended to clinicians, patients or 
policymakers.
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